Speedel Group raised CHF47.8 million (US$41 million) in equity funding, most of it from the same network of private investors and specialist investment funds that have supported the company since its formation in 1998. (BioWorld International)
Basilea Pharmaceutica AG entered a worldwide agreement with Johnson & Johnson subsidiary Cilag AG International for the development, manufacturing and marketing of its cephalosporin antibiotic ceftobiprole, which is undergoing a Phase III trial in patients with complicated skin and skin-structure infections. (BioWorld International)
Basilea Pharmaceutica AG entered a worldwide agreement with Johnson & Johnson subsidiary Cilag AG International for the development, manufacturing and marketing of its cephalosporin antibiotic ceftobiprole, which is undergoing a Phase III trial in patients with complicated skin and skin-structure infections. (BioWorld International)
